ClinicalTrials.gg
CompletedNCT04621578Updated Jun 1, 2022

Transcutaneous Electrical Acupoint Stimulation on Postoperative Dizziness in Hemifacial Spasm Patients

An interventional study of HANS 100B stimulator (4 conductors, 8 electrodes; Jisheng Co., Nanjing, China) in Transcutaneous Electrical Acupoint Stimulation, Hemifacial Spasm and Dizziness, sponsored by Peking University People's Hospital. Completed at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-06-01.

Sponsored by Peking University People's Hospital · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
86
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

To observe the prevention and treatment effect of transcutaneous electrical acupoint stimulation (TEAS) on postoperative dizziness in patients with hemifacial spasm undergoing microvascular decompression surgery, and its possible mechanisms.

Read the detailed description

Hemifacial spasm (HFS) is mainly caused by vascular compression on the roots of the VII cranial nerves from the brain stem. Microvascular decompression (MVD) is the exact surgical method for the treatment of HFS, but the incidence of dizziness and postoperative nausea and vomiting (PONV) after MVD is extremely high. Despite the use of dual antiemetic therapy during the operation, the incidence of PONV within 24 hours after MVD is still as high as 66.7%. Medication alone has limited effects on dizziness and PONV treatment after MVD. Meta-analysis shows that transcutaneous electrical acupoint stimulation (TEAS) is associated with the reduction of post-emetic remedies and the incidence of dizziness after general anesthesia, and it can be integrated into the multi-modal therapy of PONV. Therefore, the purpose of our study is to observe the prevention and treatment effect of TEAS on postoperative dizziness in patients with hemifacial spasm undergoing microvascular decompression surgery, and explore its possible mechanisms.

02

Conditions studied

  • Transcutaneous Electrical Acupoint Stimulation
  • Hemifacial Spasm
  • Dizziness
03

In context

Hemifacial Spasm

23 studies on the registry are indexed under Hemifacial Spasm; 3 are open to participants now.

This study's enrollment of 86 is above the median of 61 across 11 interventional studies indexed under Hemifacial Spasm.

Browse Hemifacial Spasm studies →

Lead sponsor

Peking University People's Hospital is the lead sponsor of 609 studies on the registry; 247 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (ASA) physical status: I-III
  • (BMI): 18-30
  • Diagnosed of hemifacial spasm
  • Undergoing microvascular decompression surgery

Exclusion criteria

Exclusion Criteria:

  • Pregnant or lactating women
  • Poorly controlled hypertension or poorly controlled diabetes, severe cardiovascular and cerebrovascular diseases and mental illness
  • Cardiac pacemakers
  • Scars on bilateral Neiguan acupoints or on the mastoid area
  • Upper limb nerve injury
  • Raynaud's syndrome
  • Motion sickness or PONV history
  • Eye diseases (glaucoma, cataracts, eye trauma, etc.) or previous eye surgery
  • Participate in other clinical trials
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
86 participants (actual)

Study arms

  • Experimental
    Transcutaneous electrical acupoint stimulation arm

    Patients will be given TEAS treatment at the maximum tolerable intensity at a frequency of 2 Hertz (Hz) after surgery in postanesthesia care unit (PACU), and after returning to the ward.

    Device: HANS 100B stimulator (4 conductors, 8 electrodes; Jisheng Co., Nanjing, China)

  • Sham comparator
    Sham stimulation arm

    Patients will use the same device, same stimulation site, and be treated at the same time points, but the lead of the device was damaged. Therefore, although the patients can see the stimulator running, there is actually no current passing through.

    Device: HANS 100B stimulator (4 conductors, 8 electrodes; Jisheng Co., Nanjing, China)

Interventions

  • DeviceHANS 100B stimulator (4 conductors, 8 electrodes; Jisheng Co., Nanjing, China)

    Stimulation sites: Mastoid area on the contralateral side of the operation, Fengchi acupoint on the contralateral side of the operation, and Neiguan acupoints on both sides. Timing of stimulation: In postanesthesia care unit (PACU) after extubation, 6 hours, 24 hours, 48 hours, and 72 hours after returning to the ward. 30-minutes treatment for each time-point.

06

What researchers measure

Primary outcomes

  1. The incidence of dizziness at 2 hours after returning to the ward on the day of surgery

    The patients and their families will be asked to record a diary about their symptoms of dizziness, nausea, vomiting and headache after surgery, and they will be followed up after surgery.

    Time frame: 2 hours after returning to the ward on the day of surgery

Secondary outcomes

  1. Numerical rating scale (NRS) score of postoperative dizziness

    A 0-10 point numerical rating scale (NRS) will be used for evaluation of the severity of postoperative dizziness. 0 means no dizziness, and 10 means very severe dizziness. The degree of dizziness worsens as the number increases.

    Time frame: In PACU after extubation, and 2 hours, 6 hours, 24 hours, 48 hours, 72 hours after returning to the ward.

  2. The incidence and severity of postoperative nausea

    Nausea severity will be evaluated by a 0-10 point numerical rating scale (NRS). 0 means no nausea, and 10 means very severe nausea. The degree of nausea worsens as the number increases.

    Time frame: In PACU after extubation, and 2 hours, 6 hours, 24 hours, 48 hours, 72 hours after returning to the ward.

  3. The number of vomiting after surgery

    Vomiting times after surgery.

    Time frame: In PACU after extubation, and 2 hours, 6 hours, 24 hours, 48 hours, 72 hours after returning to the ward.

  4. The use of remedial drugs after surgery

    Drug used for anti-emetic or anti-dizziness after surgery.

    Time frame: From the day of surgery to 72 hours after surgery.

  5. The incidence and severity of postoperative headache

    Headache severity will be evaluated by a 0-10 point numerical rating scale (NRS). 0 means no headache, and 10 means very severe headache. The degree of headache worsens as the number increases.

    Time frame: In PACU after extubation, and 2 hours, 6 hours, 24 hours, 48 hours, 72 hours after returning to the ward.

  6. Changes in intraocular pressure before and after surgery

    Intraocular pressure will be measured by a non-contact tonometer before and after surgery by the same operator.

    Time frame: Before anesthesia induction, and before leaving PACU on the day of surgery.

  7. Gastrin and 5-Hydroxytryptamine (5-HT) levels in serum and cerebrospinal fluid

    Peripheral blood will be collected before and after surgery, and cerebrospinal fluid (CSF) will be collected during the surgery.

    Time frame: The peripheral blood samples will be collected on the day of surgery, and on postoperative day 1. The CSF samples will be collected on the day of surgery.

  8. Postoperative complications monitoring

    The Clavien-Dindo grading system will be used.

    Time frame: From the day of surgery to the day of discharge.

  9. Postoperative duration of stay in hospital

    The duration when patients stay in hospital after surgery.

    Time frame: From the day of surgery to the day of discharge.

  10. Dizziness symptoms 4 weeks after discharge

    Patients will be followed up by telephone 4 weeks after discharge, and the Dizziness Handicap Inventory (DHI) will be used for measurement.

    Time frame: 4 weeks after discharge.

07

Study locations

1 site
  • Peking University People's Hospital
    Beijing, Beijing 100044, China
08

References and documents

Publications

  • Miller LE, Miller VM. Safety and effectiveness of microvascular decompression for treatment of hemifacial spasm: a systematic review. Br J Neurosurg. 2012 Aug;26(4):438-44. doi: 10.3109/02688697.2011.641613. Epub 2011 Dec 15. PubMed 22168965 ↗
  • Thongrong C, Chullabodhi P, Kasemsiri P, Kitkhuandee A, Plailaharn N, Sabangban L, Jimarsa T. Effects of Intraoperative Dexamethasone and Ondansetron on Postoperative Nausea and Vomiting in Microvascular Decompression Surgery: A Randomized Controlled Study. Anesthesiol Res Pract. 2018 Nov 11;2018:6297362. doi: 10.1155/2018/6297362. eCollection 2018. PubMed 30534153 ↗
  • Chen J, Tu Q, Miao S, Zhou Z, Hu S. Transcutaneous electrical acupoint stimulation for preventing postoperative nausea and vomiting after general anesthesia: A meta-analysis of randomized controlled trials. Int J Surg. 2020 Jan;73:57-64. doi: 10.1016/j.ijsu.2019.10.036. Epub 2019 Nov 6. PubMed 31704425 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 1, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04621578
Responsible party
Yi Feng, MD (Chief of the Anesthesiology Department, Peking University People's Hospital) — Principal investigator
First posted
Nov 9, 2020
Start date
Dec 6, 2020
Primary completion
Jun 25, 2021
Completion
Jul 30, 2021
Last update
Jun 1, 2022

Study contacts

Yi Feng, MD, PhD
principal investigator · Peking University People's Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion